Physician profile
John Ghobrial
NPI 1508868290
$5,441.67
in general payments reported to CMS, 2019-2025
21 companies · $864 in 2025
The $864 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $166 · 2021: $690 · 2022: $897 · 2023: $1,079 · 2024: $1,274 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,199 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,198.98 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,309.88 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $758.04 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $699.98 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $677.11 | 2019-2025 | Rocklatan, Rhopressa, Eysuvis |
| Bausch & Lomb Americas INC. | $337.69 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Horizon Therapeutics Plc | $286.11 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $254.72 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $229.41 | 2019-2022 | |
| Allergan, INC. | $186.10 | 2021 | |
| Harrow Eye, LLC | $168.63 | 2024-2025 | Vevye |
| Ivantis, INC | $127.25 | 2019 | |
| Coopervision INC. | $84.93 | 2019-2023 | Myday Contact Lens |
| Beaver-Visitec International, INC. | $69.95 | 2021-2023 | |
| Tarsus Pharmaceuticals, INC. | $66.67 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.64 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $47.35 | 2022-2025 | Oxervate |
| Abbvie INC. | $27.44 | 2022-2023 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Amgen INC. | $15.29 | 2025 | Tepezza |
| Shire North American Group INC | $14.91 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ghobrial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.